{"ticker": {"uuid": "1e83ff7c-8562-45a4-b475-b8eb4a9b0834", "symbol": "EPRX", "name": "Eupraxia Pharmaceuticals Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Eupraxia Pharmaceuticals (EPRX) reshapes leadership and expands Vancouver-Seattle hubs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQcTA2TGFWWmtvTFlUQmNlLTczQ0RIY3ZNeTN4eUhGS3p0T1U1bUU1bFVjM2hmdVlaYnEwYWRyTm5NbDBaaUZBUTYyTEszNVV3WkdsRmVnSE02MFoteHZJempfc2QtZlRMcVVOdzN2N01PM2Q0ekdQUlBDM0FhSHlqeTdLbkFuZXVxMVp2X3lxTkI2M0pvMnZOblRqbWktVlRMdXdyQVhaSWhhRy1KOEdBVDRVbDhPNW5TWU53cWVfUkNwUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T17:26:29+00:00", "published_display": "15 Jul 2026 17:26", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Announces Executive Leadership Changes", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/eupraxia-pharmaceuticals-announces-executive-leadership-203711833.html", "source_name": "MT Newswires", "published_at": "2026-07-13T20:37:11+00:00", "published_display": "13 Jul 2026 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (NASDAQ: EPRX) adds senior leaders, prepares for Q4 2026 RESOLVE data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPLWZTUlYybEhUd0hQSFdfVHlPalpYUUxQREdZS29PeVlmR3pZZS1xblZXYS10OTlzSERLMGJJRnpURXczNFhGLW81VHV2T3U2eDY3TDBzazlqcGh2NDlaQi1yUnVTNGdjY1pqSGNqaHhYRXRwaTFmLTRDYzN5dFVha2lEQkF0eUU4S25ZempnMnFUSFh4NWVNcVBVOWY0M1RGSksyd3RTOXNXNG9TdWM4NnZQMWFkVWpXOTU4cTZ1RWFJUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:16:07+00:00", "published_display": "13 Jul 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxPNmFlRWlDQnBhQUpBRHNPMVI5WmdUVVNvck5ydGRYRFg4M0F0V2JYblVtVzhDRzROS0t6X3JiWHlnaUhQbS1NY0ZaS3RYY0oweVVYaURCNElZNFNTcGlTcHdhQmZlMHc3YVFlOURkWEZuNTV0YnptOGNqMVBsaHFYSXJsdndIWFlXbG5sbXp6SWVYSFpXeFVlaU9za3k0NGN5VXh4X2pBaU9lRFROR09jZGNQSlZwbWx2MFdLTEZyOElYSGo3NHp3NHNWMmJaNVl1TlIzXzFtZzZPU3U5bHZEOG9jdDFlWUhpUW15cHluT0hLcE1kdFlhNnlha203WjAxcFl1S1V6WnNmMUJ0VVE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T20:05:00+00:00", "published_display": "13 Jul 2026 20:05", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New drug-development leaders join Eupraxia as it readies Phase 3 push", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNemU4dEk4ZHBXRUFGYy0zYjdhLWJmRGNISFU0Z1ZLaXNOLVFZM1dOWmw0V3NFbklZdWJRU2xJdUtXUXh4eHpKUXdIblpDNFF6cjJRZm1TblNmQ3M4bUVLQjFrYnFOSm9MZ1JQbG1xV3MzTjNHWWJpYkhPRHFHeG5BV2xIM1l4bmp4ang3NkpCUEliOWdhdjQyXzd3M0lmU2VwSEUxQ0U2Z0dYMVEzaURNNUJydFRIV0hlM3hOMQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:05:00+00:00", "published_display": "13 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (EPRX) Gains 3.8% as Biotech Sector Shows Resilience \u2013 Key Levels to Watch - Long Setup Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQOUZ6eUpUOEZQTkZWVlEzX1VFWmdJZmg3cnNXUWhwYll5MjVlLTNxQlNjUGRnblZuYmdfb1laalZTTUd1cUo4cXJGaU0wbUY5UDl0WG83NmxpVE5uNXExRUtCM2FONUdQd19TN0l4UXl1NFVVcHdDbzNTS1QtTFpoUzJ3d0NpWFZDaUdMdVdOTHp1cVNjOUZ0djktLW84dXc4NVFyWUZkUGhOWWRwTTR6bkxpNzRQdnlkQ0RlVlVWT2paVllJUHV1Tl9FemtQREFm?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (EPRX) Gains 3.8% as Biotech Sector Shows Resilience \u2013 Key Levels to Watch - Triple MA Cross", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOb3k5WUEtRm1qZkNNZGpwNjVuWUJoa293QzRzT0NBdTNLdkJjZmkzLW1pUEtVMlkzVHBLdTBfejh5SFpaeTlHVFZhSFhiZGdNX3l5SFIzcWJhQlVUb0E2VFNsa08xZDhqLXh3Q1Q1eGE5b3dDRnIxTFFPZkV6UUZESUVJNU9QY2VVZHFqTGFNS291eEg0TVpOU1FBc2otOVNBaVdGSWlYc1hCSlY0YmhXeEc3ZnFYbGVxNjRaOVotVHdDSDBFLTQyMmRGLWg0VVFNTHpn?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (EPRX) adds three drug development and commercialization experts to board", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOek5xa1prdkhmaGJUdXZmc0VSdGFtRzhSR2s3TXdMSF9TRzNUTk9ManNacW5wMXlxMThNZS0xc2dxNzMtM1huZUxUYmN5VUNtY0RueHh4VTRvSkhWQjNCT2dVNWhGVGdnU2lzcDFnTGtzRGxNc3RjU1hvM3ozUnNRVjF2b3NGeng5amx2S0w1dU84QXFfbW92Z0Nha0phcnZadDY0aHZuc2xlc01ENllfdnBlUmwzb1htZkFXVjAzOF9RQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T20:21:07+00:00", "published_display": "07 Jul 2026 20:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/eupraxia-pharmaceuticals-strengthens-board-three-120000733.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T12:00:00+00:00", "published_display": "07 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia taps three biotech veterans for board as EP-104GI milestones loom", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNSlpiSlRXRXFkOTVPZFBOb1dqa05fOTk3ckV6RkNLcC1zdmJyeFl6RnpfMnpkN3lfcXM1THNISFJHWlNxa3hpZ0FYYk85cmhzUXhkd3RaQWY2eXlUeDFGSUNJRGRnNENtZjlIakNiTHp1VEdWYXFraXJEc1F0MEd2NWVrVmFRdHh4a2tEUTBKaThQVEFDX3o4ZEVsM29fWEtGakJQdXRPLS1rXzFaZ050RjVlTjlFUFZM?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer initiates Eupraxia stock with Outperform rating By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQSHJMYTJ1UG03bW53c25kOU5QaTI2cWdKczhtVU05Mm11eFpYQ3FWS2ZZdWYybFdyVzRtREsxYXBfaFJtczdxV1c4ZjdwOTRWenRmczF2aEttZkhGUExuQkY3X0RGa1hITXpCSmNhZEdldlR6NjRWeE9FSE9WN21lOUs5WmdFam5GS1dFSFR3UGt3Q1pCTXpQZXhRTmZ3UG9ZZXFESVctUGl6M0hYWnA2WU1ZdVJwNWZnQWx2TQ?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-25T21:20:47+00:00", "published_display": "25 Jun 2026 21:20", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strong support as Eupraxia (NASDAQ: EPRX) shareholders elect seven directors, renew KPMG", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOZlZXdkxiRXlmcW8xRmNpMDVobGdreHZ1YVNMTUZPR0hPVS1QMlgyLV9jRGlQR0YzQXVqZDBoM203SGhyUHZPZG9iXzRrRWhpM2JHZTBLaWpVa3ZtQ2ZucjJEdk9wemViZExsdTJQa0dxS2ZVbktPMmhmbktaVW5BbFh0OFFWcFRwdE56NGdMcFEtM3VEVHM1Qm1mRXhISUhZUTlzaEQ0bVl1ZHFmRW1QOHFlUVl0bTlHWXo2VkJQQkljUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNSzJzNk5qTlFKOEVocWRzSXhfWG91OV9yblcwQmVpd1FxOWtHYVA0YjVHNm5xeXgySTZDNzNveWtsdUJfZUdPLUxzNy1ndE1jZUJCaE9aTGN6aGQ4SkJrS1EzX0s3Q0JlRHFKOVIwWnYwRDFaeHN5dVowRHkwLVNNa3p2TEpKRUo2dk4yVmFaRDNLU2k2ek5ZRUVNZkdOQlVNZVdhMFBYbTVuYzd6U05JX0lKUDRLSUstWGNRa2FNdXU2MHdkSm1nVjI4aWNQYnVwQmwtRjZmaU5zMWZWek1IenJkSjZLTXRKRFlJb3h1TzdUZDR3X1EyRw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Inc (EPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE9fRFNlLTd6UFlJckRsQ3dBbGs1TmZnS1o2dUtqd3JrNFowVzdITVIxbnFYeWJIekQ0X255azY4NndtWmF4WHE0cExZNEhaeVQzSDVpajNPaEtnY01lRU1LOVB0Z0RfTlQ5ZjR5ckFsRQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T17:42:31+00:00", "published_display": "18 Jun 2026 17:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eupraxia-pharmaceuticals-participate-jefferies-global-120000928.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T12:00:00+00:00", "published_display": "28 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Eupraxia heads to New York for Jefferies health conference June 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPbUNSM0Z0VEdvdUNpeVdoTHJmcVowdjE0QzJPUHZwcVpzTHV6eVd2V2hkZlNXY2k3NGkyaExBU1Zaei1vWlplbko2Q2tMeDdLRlFTZDRTVkZxakFsOTRnOXVuNTBlekFwVFM1VTQ0UUFUcnRYTmp1LV9BS1k2dHlKYUY5a1AxQXBFeDZxckJ6NGlZTVNlbHBFMlF2VlJPbjcxU0V6RGtrUU1pTEpXd0x0NWszRjd3blJoLWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel Initiates Eupraxia Pharmaceuticals at Buy With CA$34.37 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/stifel-initiates-eupraxia-pharmaceuticals-buy-110646745.html", "source_name": "MT Newswires", "published_at": "2026-05-21T11:06:46+00:00", "published_display": "21 May 2026 11:06", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Analyst Forecast: $EPRX Given $25 Price Target | EPRX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOSC11T2h1U0RjampIT0J6dW1iRjMzbTgwckVCWjIwamtleXFOVEFOeno3V1FrTGNlaERucFpFVWl1ZWcyOE1iQ3A3RmNMUFJpT2xqMVFTMDlYZy0xdGs5V1RQUUJlaUkxSFZaUVJiWTdDajVJeGlkNEhGeXJidzJfMUtrVWd2bG5CbGp6U1VQSWtIRUU?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Q1 Loss Narrows", "summary": "", "url": "https://finance.yahoo.com/news/eupraxia-pharmaceuticals-q1-loss-narrows-212146646.html", "source_name": "MT Newswires", "published_at": "2026-05-12T21:21:46+00:00", "published_display": "12 May 2026 21:21", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNaXRYci15bTk3UUtOUnVVbklMYnYwd2tXdXdiNDdlNkg4M19kbkJrNHNhN1o3a05hU3Nudi00RW5WQ3BMSTdPeFNwQ3lxdEt5VVZMZXY4YkdqMzJDSUFGZHJhNEpta01jXzZwbl9qTGJudGh0WXlGaldLT0YyV0NXZHJ0akRJVW1MQU04bm5EWHVRRVZMZ1Bid1dDMG1TUkR3NGFKN0hNeEtOY3M0aUx6Z25OdjEzTGMxdjZoU0xhd0Z4MmMyQzN3MXJxam5jTV9DT0RiNlZONW8?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Eupraxia Pharmaceuticals\u2019 First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eupraxia-pharmaceuticals-first-release-eoehss-110000434.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T11:00:00+00:00", "published_display": "06 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eupraxia-pharmaceuticals-reports-erefs-data-110000639.html", "source_name": "GlobeNewswire", "published_at": "2026-05-05T11:00:00+00:00", "published_display": "05 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Surgeon-scientist Jeymi Tambiah joins Eupraxia as CMO", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQclgtQ3FlRi1YZ19jT3RwdEp4MkR3MnYwS2xVMlFHX1FvT0NEbWJCbGU2TjRQNnZjR1kyN1dXYzNCTDdRLTVNYi1JVmRVaGZ6dWdleTh3YmUwVVdnRGlNU25BR1lHdm8zb0J3ZlM3d3pIX2EtQ2tVWXBCb21pblFpWWQzRnkxYWRxbk1UaWo5S1pGdHBCZDA1QmsxUXQxTEcxbUZ3UjR3UjUtQnViLWFiT1FyQlU0dDFNMkVoS1BlVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Announces Pricing of US$55 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxPNEp6a0o0ZG40NGlndHVfMzZPaVVWb2xaejlxX0lfOXJZMVVFeUI5THhVZDJmVWFZRVdBQzF6VlhQcTJ4Sm1Ra294NUlVSzdqbFU1eWJNXzhQUjVPTmpMN1ByTnh6eXduaWFkYnVLeE9WS2drQVkzZGVBUTdUTnQtQzZ6bFVsOXVCMkREdF9vc1duSHZLNHlMY200UXU4RE1vZ2dmMjJvc29zU21ra3JPN0ZTcFhCVU91dHlmdEtmd0hrTldrNFRoalBhLW02bDBWbmxCM2R0R0Rkc3BjeV94SVd2bEVBbW53SXk0QmJESFBEei1uMkNKUTVoQ2l3QnFzbGVsUERQaVFjd1cxeTNELV82UDJSdzQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Eupraxia plans share sale to fund EoE, Crohn\u2019s trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPdW9qMDgxM3BMZVZ4aUdRb2hva2trUks2T2tlR3prT0F1YzNka1ZHOWFfXzcwcTA3MWhFY0o4XzRMMl9VUVd6YUlta0RxSktVM1RYQThERGZUVUJKd1l5R0wtZ0VjajlETU5ncUs4RkVBWElqLVBJWDB1MHd6Tl9MYWNmLTBWUjNaMTR5UUxqMTAzSjJMelRpY3d3eFhfLVoyWlBVYmpCa1Q?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Announces Proposed Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOdDc2NXJSdnpwUUVZVXBUbnlQM0RIM0xnMWtiQmR6MzhPZmdkYUladTZsYTQ3ZEEwN0tnVU9hLVZfQkY1QmxXQmY4ZWdlUjAwRlZ3amdKa00tZXZlem1jUHlKN2s4dWxSenBDR2FyMXVCU0R1NE5kWUtWWm9SMWl2UTk0d2QtRGdwUlo4MUh1bmJxTTVVOHBjaERFc0JTQ0JlTUVBcTJtZGdkd2JMZjlCQU82M2pTQm1XS1gya2dIc0diNFhGeFBaQ2F1RQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not At All Concerned With Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE9XZTlzZ094SXR1RGRCMm93a1huenMyQWN3RE1qYi1iT0ZTXzV4djVXeWRpSVY4THJob1BWZ1loOURvVVZFQmMyODluUXZZRF9raXk4RnFUODlTcGdZQ3ZoY01yLTQteVVCM1J3bUtWOUtTZ0w4Q2VSRm1RM0JldGM?oc=5", "source_name": "Market source", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Inc. (TSE:EPRX) surges 15%; retail investors who own 41% shares profited along with institutions", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$80.5M Biotech Funding: Eupraxia Secures Major Capital for Esophagitis Drug Development Through 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNanhJNlRzZVZuY2RldnRKby1zZ0lQTXd2bmVualprSjR5aDJ4T2xoSUNkOVNIY0JNbWpIQURNejJBdEVwSFFtaElwcjFXTVhSMUlZOUxJM3lWZ1Y2SjlWUXp6TVdOVFg0TjB1V1V0ZjlQd3ZCdzh2TUhHXzA3djloNG42eTdzMjJoQ28xSXo2WU9vQTZPVWdfUGtVcnhzX21ya2s1VFROSlMwc25XMGl2Y2xaeUU1VzB5dHYzeHJhaUI?oc=5", "source_name": "Stock Titan", "published_at": "2025-09-24T07:00:00+00:00", "published_display": "24 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmac (EPRX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9xNmdyM0RmQmgzdWN5clNtWlY2am9ObVNFaHBYRG1NV3RaNnVPeG4xMGs0VVpCZmZNZWpjYllLY1RZVms0WGZfS19YMXl3WmYwcFN3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T22:29:27+00:00", "published_display": "24 Apr 2025 22:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "symbol__ Stock Quote Price and Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE5tdlcxZ2l5eWN0MjRxX3ViQVUzZHpwbzgydWduZEF3Qm1lUktYWFJid05ma2IyTUhmOUpOaUY5cEVWVnk2WVVtUHR6bTZfUk1H?oc=5", "source_name": "CNN", "published_at": "2024-04-07T12:04:15+00:00", "published_display": "07 Apr 2024 12:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Eupraxia Pharmaceuticals (EPRX) reshapes leadership and expands Vancouver-Seattle hubs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQcTA2TGFWWmtvTFlUQmNlLTczQ0RIY3ZNeTN4eUhGS3p0T1U1bUU1bFVjM2hmdVlaYnEwYWRyTm5NbDBaaUZBUTYyTEszNVV3WkdsRmVnSE02MFoteHZJempfc2QtZlRMcVVOdzN2N01PM2Q0ekdQUlBDM0FhSHlqeTdLbkFuZXVxMVp2X3lxTkI2M0pvMnZOblRqbWktVlRMdXdyQVhaSWhhRy1KOEdBVDRVbDhPNW5TWU53cWVfUkNwUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T17:26:29+00:00", "published_display": "15 Jul 2026 17:26", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Announces Executive Leadership Changes", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/eupraxia-pharmaceuticals-announces-executive-leadership-203711833.html", "source_name": "MT Newswires", "published_at": "2026-07-13T20:37:11+00:00", "published_display": "13 Jul 2026 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (NASDAQ: EPRX) adds senior leaders, prepares for Q4 2026 RESOLVE data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPLWZTUlYybEhUd0hQSFdfVHlPalpYUUxQREdZS29PeVlmR3pZZS1xblZXYS10OTlzSERLMGJJRnpURXczNFhGLW81VHV2T3U2eDY3TDBzazlqcGh2NDlaQi1yUnVTNGdjY1pqSGNqaHhYRXRwaTFmLTRDYzN5dFVha2lEQkF0eUU4S25ZempnMnFUSFh4NWVNcVBVOWY0M1RGSksyd3RTOXNXNG9TdWM4NnZQMWFkVWpXOTU4cTZ1RWFJUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:16:07+00:00", "published_display": "13 Jul 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxPNmFlRWlDQnBhQUpBRHNPMVI5WmdUVVNvck5ydGRYRFg4M0F0V2JYblVtVzhDRzROS0t6X3JiWHlnaUhQbS1NY0ZaS3RYY0oweVVYaURCNElZNFNTcGlTcHdhQmZlMHc3YVFlOURkWEZuNTV0YnptOGNqMVBsaHFYSXJsdndIWFlXbG5sbXp6SWVYSFpXeFVlaU9za3k0NGN5VXh4X2pBaU9lRFROR09jZGNQSlZwbWx2MFdLTEZyOElYSGo3NHp3NHNWMmJaNVl1TlIzXzFtZzZPU3U5bHZEOG9jdDFlWUhpUW15cHluT0hLcE1kdFlhNnlha203WjAxcFl1S1V6WnNmMUJ0VVE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T20:05:00+00:00", "published_display": "13 Jul 2026 20:05", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New drug-development leaders join Eupraxia as it readies Phase 3 push", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNemU4dEk4ZHBXRUFGYy0zYjdhLWJmRGNISFU0Z1ZLaXNOLVFZM1dOWmw0V3NFbklZdWJRU2xJdUtXUXh4eHpKUXdIblpDNFF6cjJRZm1TblNmQ3M4bUVLQjFrYnFOSm9MZ1JQbG1xV3MzTjNHWWJpYkhPRHFHeG5BV2xIM1l4bmp4ang3NkpCUEliOWdhdjQyXzd3M0lmU2VwSEUxQ0U2Z0dYMVEzaURNNUJydFRIV0hlM3hOMQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:05:00+00:00", "published_display": "13 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (EPRX) Gains 3.8% as Biotech Sector Shows Resilience \u2013 Key Levels to Watch - Long Setup Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQOUZ6eUpUOEZQTkZWVlEzX1VFWmdJZmg3cnNXUWhwYll5MjVlLTNxQlNjUGRnblZuYmdfb1laalZTTUd1cUo4cXJGaU0wbUY5UDl0WG83NmxpVE5uNXExRUtCM2FONUdQd19TN0l4UXl1NFVVcHdDbzNTS1QtTFpoUzJ3d0NpWFZDaUdMdVdOTHp1cVNjOUZ0djktLW84dXc4NVFyWUZkUGhOWWRwTTR6bkxpNzRQdnlkQ0RlVlVWT2paVllJUHV1Tl9FemtQREFm?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (EPRX) Gains 3.8% as Biotech Sector Shows Resilience \u2013 Key Levels to Watch - Triple MA Cross", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOb3k5WUEtRm1qZkNNZGpwNjVuWUJoa293QzRzT0NBdTNLdkJjZmkzLW1pUEtVMlkzVHBLdTBfejh5SFpaeTlHVFZhSFhiZGdNX3l5SFIzcWJhQlVUb0E2VFNsa08xZDhqLXh3Q1Q1eGE5b3dDRnIxTFFPZkV6UUZESUVJNU9QY2VVZHFqTGFNS291eEg0TVpOU1FBc2otOVNBaVdGSWlYc1hCSlY0YmhXeEc3ZnFYbGVxNjRaOVotVHdDSDBFLTQyMmRGLWg0VVFNTHpn?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (EPRX) adds three drug development and commercialization experts to board", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOek5xa1prdkhmaGJUdXZmc0VSdGFtRzhSR2s3TXdMSF9TRzNUTk9ManNacW5wMXlxMThNZS0xc2dxNzMtM1huZUxUYmN5VUNtY0RueHh4VTRvSkhWQjNCT2dVNWhGVGdnU2lzcDFnTGtzRGxNc3RjU1hvM3ozUnNRVjF2b3NGeng5amx2S0w1dU84QXFfbW92Z0Nha0phcnZadDY0aHZuc2xlc01ENllfdnBlUmwzb1htZkFXVjAzOF9RQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T20:21:07+00:00", "published_display": "07 Jul 2026 20:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/eupraxia-pharmaceuticals-strengthens-board-three-120000733.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T12:00:00+00:00", "published_display": "07 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia taps three biotech veterans for board as EP-104GI milestones loom", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNSlpiSlRXRXFkOTVPZFBOb1dqa05fOTk3ckV6RkNLcC1zdmJyeFl6RnpfMnpkN3lfcXM1THNISFJHWlNxa3hpZ0FYYk85cmhzUXhkd3RaQWY2eXlUeDFGSUNJRGRnNENtZjlIakNiTHp1VEdWYXFraXJEc1F0MEd2NWVrVmFRdHh4a2tEUTBKaThQVEFDX3o4ZEVsM29fWEtGakJQdXRPLS1rXzFaZ050RjVlTjlFUFZM?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer initiates Eupraxia stock with Outperform rating By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQSHJMYTJ1UG03bW53c25kOU5QaTI2cWdKczhtVU05Mm11eFpYQ3FWS2ZZdWYybFdyVzRtREsxYXBfaFJtczdxV1c4ZjdwOTRWenRmczF2aEttZkhGUExuQkY3X0RGa1hITXpCSmNhZEdldlR6NjRWeE9FSE9WN21lOUs5WmdFam5GS1dFSFR3UGt3Q1pCTXpQZXhRTmZ3UG9ZZXFESVctUGl6M0hYWnA2WU1ZdVJwNWZnQWx2TQ?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-25T21:20:47+00:00", "published_display": "25 Jun 2026 21:20", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strong support as Eupraxia (NASDAQ: EPRX) shareholders elect seven directors, renew KPMG", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOZlZXdkxiRXlmcW8xRmNpMDVobGdreHZ1YVNMTUZPR0hPVS1QMlgyLV9jRGlQR0YzQXVqZDBoM203SGhyUHZPZG9iXzRrRWhpM2JHZTBLaWpVa3ZtQ2ZucjJEdk9wemViZExsdTJQa0dxS2ZVbktPMmhmbktaVW5BbFh0OFFWcFRwdE56NGdMcFEtM3VEVHM1Qm1mRXhISUhZUTlzaEQ0bVl1ZHFmRW1QOHFlUVl0bTlHWXo2VkJQQkljUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNSzJzNk5qTlFKOEVocWRzSXhfWG91OV9yblcwQmVpd1FxOWtHYVA0YjVHNm5xeXgySTZDNzNveWtsdUJfZUdPLUxzNy1ndE1jZUJCaE9aTGN6aGQ4SkJrS1EzX0s3Q0JlRHFKOVIwWnYwRDFaeHN5dVowRHkwLVNNa3p2TEpKRUo2dk4yVmFaRDNLU2k2ek5ZRUVNZkdOQlVNZVdhMFBYbTVuYzd6U05JX0lKUDRLSUstWGNRa2FNdXU2MHdkSm1nVjI4aWNQYnVwQmwtRjZmaU5zMWZWek1IenJkSjZLTXRKRFlJb3h1TzdUZDR3X1EyRw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Inc (EPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE9fRFNlLTd6UFlJckRsQ3dBbGs1TmZnS1o2dUtqd3JrNFowVzdITVIxbnFYeWJIekQ0X255azY4NndtWmF4WHE0cExZNEhaeVQzSDVpajNPaEtnY01lRU1LOVB0Z0RfTlQ5ZjR5ckFsRQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T17:42:31+00:00", "published_display": "18 Jun 2026 17:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eupraxia-pharmaceuticals-participate-jefferies-global-120000928.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T12:00:00+00:00", "published_display": "28 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Eupraxia heads to New York for Jefferies health conference June 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPbUNSM0Z0VEdvdUNpeVdoTHJmcVowdjE0QzJPUHZwcVpzTHV6eVd2V2hkZlNXY2k3NGkyaExBU1Zaei1vWlplbko2Q2tMeDdLRlFTZDRTVkZxakFsOTRnOXVuNTBlekFwVFM1VTQ0UUFUcnRYTmp1LV9BS1k2dHlKYUY5a1AxQXBFeDZxckJ6NGlZTVNlbHBFMlF2VlJPbjcxU0V6RGtrUU1pTEpXd0x0NWszRjd3blJoLWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel Initiates Eupraxia Pharmaceuticals at Buy With CA$34.37 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/stifel-initiates-eupraxia-pharmaceuticals-buy-110646745.html", "source_name": "MT Newswires", "published_at": "2026-05-21T11:06:46+00:00", "published_display": "21 May 2026 11:06", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Analyst Forecast: $EPRX Given $25 Price Target | EPRX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOSC11T2h1U0RjampIT0J6dW1iRjMzbTgwckVCWjIwamtleXFOVEFOeno3V1FrTGNlaERucFpFVWl1ZWcyOE1iQ3A3RmNMUFJpT2xqMVFTMDlYZy0xdGs5V1RQUUJlaUkxSFZaUVJiWTdDajVJeGlkNEhGeXJidzJfMUtrVWd2bG5CbGp6U1VQSWtIRUU?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Q1 Loss Narrows", "summary": "", "url": "https://finance.yahoo.com/news/eupraxia-pharmaceuticals-q1-loss-narrows-212146646.html", "source_name": "MT Newswires", "published_at": "2026-05-12T21:21:46+00:00", "published_display": "12 May 2026 21:21", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNaXRYci15bTk3UUtOUnVVbklMYnYwd2tXdXdiNDdlNkg4M19kbkJrNHNhN1o3a05hU3Nudi00RW5WQ3BMSTdPeFNwQ3lxdEt5VVZMZXY4YkdqMzJDSUFGZHJhNEpta01jXzZwbl9qTGJudGh0WXlGaldLT0YyV0NXZHJ0akRJVW1MQU04bm5EWHVRRVZMZ1Bid1dDMG1TUkR3NGFKN0hNeEtOY3M0aUx6Z25OdjEzTGMxdjZoU0xhd0Z4MmMyQzN3MXJxam5jTV9DT0RiNlZONW8?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals\u2019 First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eupraxia-pharmaceuticals-first-release-eoehss-110000434.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T11:00:00+00:00", "published_display": "06 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eupraxia-pharmaceuticals-reports-erefs-data-110000639.html", "source_name": "GlobeNewswire", "published_at": "2026-05-05T11:00:00+00:00", "published_display": "05 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Surgeon-scientist Jeymi Tambiah joins Eupraxia as CMO", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQclgtQ3FlRi1YZ19jT3RwdEp4MkR3MnYwS2xVMlFHX1FvT0NEbWJCbGU2TjRQNnZjR1kyN1dXYzNCTDdRLTVNYi1JVmRVaGZ6dWdleTh3YmUwVVdnRGlNU25BR1lHdm8zb0J3ZlM3d3pIX2EtQ2tVWXBCb21pblFpWWQzRnkxYWRxbk1UaWo5S1pGdHBCZDA1QmsxUXQxTEcxbUZ3UjR3UjUtQnViLWFiT1FyQlU0dDFNMkVoS1BlVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Announces Pricing of US$55 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxPNEp6a0o0ZG40NGlndHVfMzZPaVVWb2xaejlxX0lfOXJZMVVFeUI5THhVZDJmVWFZRVdBQzF6VlhQcTJ4Sm1Ra294NUlVSzdqbFU1eWJNXzhQUjVPTmpMN1ByTnh6eXduaWFkYnVLeE9WS2drQVkzZGVBUTdUTnQtQzZ6bFVsOXVCMkREdF9vc1duSHZLNHlMY200UXU4RE1vZ2dmMjJvc29zU21ra3JPN0ZTcFhCVU91dHlmdEtmd0hrTldrNFRoalBhLW02bDBWbmxCM2R0R0Rkc3BjeV94SVd2bEVBbW53SXk0QmJESFBEei1uMkNKUTVoQ2l3QnFzbGVsUERQaVFjd1cxeTNELV82UDJSdzQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Eupraxia plans share sale to fund EoE, Crohn\u2019s trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPdW9qMDgxM3BMZVZ4aUdRb2hva2trUks2T2tlR3prT0F1YzNka1ZHOWFfXzcwcTA3MWhFY0o4XzRMMl9VUVd6YUlta0RxSktVM1RYQThERGZUVUJKd1l5R0wtZ0VjajlETU5ncUs4RkVBWElqLVBJWDB1MHd6Tl9MYWNmLTBWUjNaMTR5UUxqMTAzSjJMelRpY3d3eFhfLVoyWlBVYmpCa1Q?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Announces Proposed Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOdDc2NXJSdnpwUUVZVXBUbnlQM0RIM0xnMWtiQmR6MzhPZmdkYUladTZsYTQ3ZEEwN0tnVU9hLVZfQkY1QmxXQmY4ZWdlUjAwRlZ3amdKa00tZXZlem1jUHlKN2s4dWxSenBDR2FyMXVCU0R1NE5kWUtWWm9SMWl2UTk0d2QtRGdwUlo4MUh1bmJxTTVVOHBjaERFc0JTQ0JlTUVBcTJtZGdkd2JMZjlCQU82M2pTQm1XS1gya2dIc0diNFhGeFBaQ2F1RQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not At All Concerned With Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE9XZTlzZ094SXR1RGRCMm93a1huenMyQWN3RE1qYi1iT0ZTXzV4djVXeWRpSVY4THJob1BWZ1loOURvVVZFQmMyODluUXZZRF9raXk4RnFUODlTcGdZQ3ZoY01yLTQteVVCM1J3bUtWOUtTZ0w4Q2VSRm1RM0JldGM?oc=5", "source_name": "Market source", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Inc. (TSE:EPRX) surges 15%; retail investors who own 41% shares profited along with institutions", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$80.5M Biotech Funding: Eupraxia Secures Major Capital for Esophagitis Drug Development Through 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNanhJNlRzZVZuY2RldnRKby1zZ0lQTXd2bmVualprSjR5aDJ4T2xoSUNkOVNIY0JNbWpIQURNejJBdEVwSFFtaElwcjFXTVhSMUlZOUxJM3lWZ1Y2SjlWUXp6TVdOVFg0TjB1V1V0ZjlQd3ZCdzh2TUhHXzA3djloNG42eTdzMjJoQ28xSXo2WU9vQTZPVWdfUGtVcnhzX21ya2s1VFROSlMwc25XMGl2Y2xaeUU1VzB5dHYzeHJhaUI?oc=5", "source_name": "Stock Titan", "published_at": "2025-09-24T07:00:00+00:00", "published_display": "24 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmac (EPRX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9xNmdyM0RmQmgzdWN5clNtWlY2am9ObVNFaHBYRG1NV3RaNnVPeG4xMGs0VVpCZmZNZWpjYllLY1RZVms0WGZfS19YMXl3WmYwcFN3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T22:29:27+00:00", "published_display": "24 Apr 2025 22:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "symbol__ Stock Quote Price and Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE5tdlcxZ2l5eWN0MjRxX3ViQVUzZHpwbzgydWduZEF3Qm1lUktYWFJid05ma2IyTUhmOUpOaUY5cEVWVnk2WVVtUHR6bTZfUk1H?oc=5", "source_name": "CNN", "published_at": "2024-04-07T12:04:15+00:00", "published_display": "07 Apr 2024 12:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 73, "total_relevant": 53, "sentiment_summary": {"positive": 16, "negative": 3, "neutral": 34, "score": 55, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 16.3, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 10.19, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 6.68, "latest_week": "2026-07-10", "one_week_move": -0.1, "four_week_move": 10.6, "twelve_week_move": -5.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.445571, "market_dynamics_buy_signal": false, "relative_strength": -14.098493, "fair_value_gap": 41.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 42.9221, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.1% over one week, +10.6% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 54, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 8}, {"label": "GlobeNewswire", "count": 8}, {"label": "MT Newswires", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "dars.gov.et", "count": 2}, {"label": "Quiver Quantitative", "count": 2}, {"label": "TIKR.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 19}, {"label": "Analyst action", "count": 3}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.1% over one week, +10.6% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Eupraxia Pharmaceuticals (EPRX) reshapes leadership and expands Vancouver-Seattle hubs"}], "updated_at": "2026-07-18T06:14:36.715215+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}